Atara Biotherapeutics
Biotechnology, 2340 Conejo Spectrum St, Thousand Oaks, California, 91320, United States, 201-500 Employees
Phone Number: 80********
Who is ATARA BIOTHERAPEUTICS
Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases in...
Read More
-
Headquarters: 2340 Conejo Spectrum St, Thousand Oaks, California, 91320, United States
-
Date Founded: 2012
-
Employees: 201-500
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 621511 |
Show More
Does something look wrong? Fix it. | View contact records from ATARA BIOTHERAPEUTICS
Atara Biotherapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Atara Biotherapeutics
Answer: Atara Biotherapeutics's headquarters are located at 2340 Conejo Spectrum St, Thousand Oaks, California, 91320, United States
Answer: Atara Biotherapeutics's phone number is 80********
Answer: Atara Biotherapeutics's official website is https://atarabio.com
Answer: Atara Biotherapeutics's revenue is $50 Million to $100 Million
Answer: Atara Biotherapeutics's SIC: 2834
Answer: Atara Biotherapeutics's NAICS: 621511
Answer: Atara Biotherapeutics has 201-500 employees
Answer: Atara Biotherapeutics is in Biotechnology
Answer: Atara Biotherapeutics contact info: Phone number: 80******** Website: https://atarabio.com
Answer: Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month